Table 2 Comparation of positive C-peptide among different studies using ultra-sensitive assay
Group (Country) | UNIFESP (BR) | Wang L, et al. [10] (USA) | Oram RA, et al. [29] (UK) | Davis AK et al. [5] (USA) | Rickels MR et al. [27] (USA) |
|---|---|---|---|---|---|
N | 138 | 182 | 74 | 919 | 63 |
Age (Mean or Median) (sd or range) | 26 (6–52) | 39(9–85) | 16(9–23) | 37.2 ± 18.9 (5–88) | 18–65 |
Diabetes Duration (yr.) Median (range) | 17 (3–34) | 15 (0–73) | 30 (19–41) | 13 (3–81) | > 2 |
Assay sensitivity detection | Mercodia® 1.5 pmol/l | Mercodia® 1.5 pmol/l | Mercodia® 1.5 pmol/l | Tosoh Bioscience® 17 pmol/L | Tosoh Bioscience® 7 pmol/L |
Positive C-peptide | FCP > 1.5 pmol/L 55% | FCP > 1.5 pmol/L 63% | FCP > 3.3 pmol/l 73% | Non-FCP > 17 pmol/L 29% | Peak in the MMT > 7 pmol/L 76% |
A1c (%) | 8.7 + 1.6 | 7.4 + 1.1 | 7.9 (7.2–9.0) | 8.0 + 1.5 | 7.6 + 0.7 |